Premium
Neoadjuvant immunotherapy for melanoma
Author(s) -
Lee Ann Y.,
Brady Mary S.
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26229
Subject(s) - medicine , immunotherapy , melanoma , adjuvant , oncology , blockade , neoadjuvant therapy , clinical trial , metastatic melanoma , ipilimumab , cancer , cancer research , receptor , breast cancer
Clinical trials have demonstrated the efficacy of immunotherapy, especially checkpoint blockade inhibitors, in the treatment of patients with metastatic melanoma. More recently, improvements in survival have been reported in patients with high‐risk resectable melanoma when these agents are used in the adjuvant setting. Increasing interest in neoadjuvant immunotherapy for high‐risk resectable melanoma has been fueled by early reports of significant efficacy. We review the rationale and data behind utilizing neoadjuvant immunotherapy.